Previous 10 | Next 10 |
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) is expected to report $0.57 for Q3 2023
2023-11-07 18:23:13 ET More on Teva Pharmaceutical Teva: Focus On Innovation And Growth Means The Times They Are A Changing Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript) The Mighty Teva Pharmac...
2023-11-07 17:06:45 ET More on Teva Pharmaceutical Teva: Focus On Innovation And Growth Means The Times They Are A Changing Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript) The Mighty Teva Pharmac...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's...
2023-11-07 12:53:17 ET More on AbbVie, GSK, etc. Arexvy Puts GSK Back On The Growth Prescription (Rating Upgrade) GSK plc (GSK) Q3 2023 Earnings Call Transcript GSK plc 2023 Q3 - Results - Earnings Call Presentation J&J’s patent win against Viatris...
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
92% of patients with Huntington's disease (HD) chorea achieved optimal dosing by week 12 with treatment on the AUSTEDO 4-week patient titration kit according to early results from the START study Additional results further reinforce the efficacy and tolerability of AUSTEDO from an analysi...
RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone 1 In the RISE study, UZEDY significantly prolonged time to impending relapse...
2023-10-30 18:50:40 ET More on Theravance Biopharma, Teva Pharmaceutical, etc. Viatris: Get Paid 5%, Before Growth Materializes Viatris' Survival Guide: Strategic Divestitures And Margins Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...